HomeAI · summaries
Storia in 8 fonti
Cancer cases weigh down Abivax’s Phase 3 maintenance data in ulcerative colitis
Abivax has proclaimed that its maintenance trial in ulcerative colitis delivered 'landmark' results, and the drug's safety profile has previously been one of its main potential selling points. But Wall Street was rattled by malignancy events that call this into question.
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
statnews.com
Abivax ulcerative colitis drug shows strong efficacy, but cases of cancer raise concerns
Abivax said its experimental treatment for ulcerative colitis showed significant efficacy in a closely watched trial, but shares of the company tanked on safety concerns.
- ·
biopharmadive.com
AbiVax falls as safety worries cloud ‘landmark’ immune drug results
A handful of cancer cases reported among treatment recipients overshadowed efficacy results analysts described as “best-in-disease” and sent shares down more than 30%.
